[ad_1]
The drug, developed by scientists in the UK to treat new types of patients with the coronavirus (Covid-19), is being tested at the Hospital of the University of Southampton. Trials of the drug “SNG-001” administered by British biotech company Synairgen are expected to be completed in late June.
Richard Marsden, CEO of the Soutair-based Synairgen company, stated that the protein “beta interferon”, which is part of the body’s first line of defense against viral viruses, is used in drug therapy. Claiming that this protein production is suppressed because the coronavirus weakens the immune system, Marsden said: “It is a special formulation of interferon beta that is administered directly to the airways while our drug is virus. I hope a direct dose protein has a strong antiviral response even in patients with weakened immune systems. “
BATTLE VIRUSES INCREASE TALENT
The goal of beta interferon is to increase the body’s ability to fight the virus, especially in those whose immune systems are weakened. With the drug SNG-001, its goal is to prevent the need for intensive care and respiratory equipment in the most serious cases of coronavirus.
Synairgen officials stated that drug trials positively improve the immune system of patients with asthma and other chronic lung conditions, while the drug needs to undergo more rigorous clinical investigation before starting to be applied to patients with Covid-19.
TEST 75 PEOPLE
While attempts to make interferon beta be used as a treatment for patients with coronavirus, which are also widely used in the treatment of MS disease, drug trials have so far been conducted with 75 volunteers. Hearts participating in drug trials will not know what treatment is applied to them until the study ends. “We will see a good improvement in the health of patients taking the drug,” said Tom Wilkinson, a professor at the University of Southampton, who chaired the drug trials.
Synairgen officials said the coronavirus drug studies, which are expected to be completed in late June, will conduct more trials in infected patients before they are used routinely, even if they are promising.
Synairgen CEO Richard Marsden says it is possible to start producing the drug as soon as clinical research with suppliers ends, while predicting that mass production will be possible by the end of the year if the drug gives positive results.
On the other hand, as the University of Oxford vaccination studies against the coronavirus continue, British Prime Minister Boris Johnson will organize an international conference that will focus on the successful continuation of these vaccines and will stop the spread of the coronavirus. (IHA)
[ad_2]
